Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Martin, V. [1 ]
Tassorelli, C. [2 ]
Ettrup, A. [3 ]
Hirman, J. [4 ]
Cady, R. [5 ]
机构：
[1] UC Headache & Facial Pain Ctr, Cincinnati, OH USA
[2] IRCCS C Mondino Fdn, Pavia, Italy
[3] H Lundbeck & Co AS, Copenhagen, Denmark
[4] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[5] Lundbeck La Jolla Res Ctr, San Diego, CA USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0289
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [1] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
    Martin, V.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 105 - 106
  • [2] Eptinezumab for migraine prevention in patients 50 years or older: A subgroup analysis of PROMISE-1 and PROMISE-2
    Martin, V. T.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    HEADACHE, 2021, 61 : 125 - 126
  • [3] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, V.
    Nagy, A. J.
    Janelidze, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 17 - 17
  • [4] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, V.
    Nagy, A. J.
    Janelidze, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 25 - 25
  • [5] Patients With Migraine Who Achieved a ≥75% Reduction in Monthly Migraine Days With Eptinezumab Treatment: Subgroup Analysis of PROMISE-1 and PROMISE-2
    Lipton, R. B.
    Charleston, L.
    Tassorelli, C.
    Brevig, T.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 113 - 114
  • [6] Patients with migraine who achieved a ≥75% reduction in monthly migraine days with eptinezumab treatment: Subgroup analysis of PROMISE-1 and PROMISE-2
    Lipton, R. B.
    Charleston, L.
    Tassorelli, C.
    Brevig, T.
    Hirman, J.
    Cady, R.
    HEADACHE, 2021, 61 : 135 - 136
  • [7] Consistent reductions in migraine frequency with eptinezumab treatment in patients with migraine stratified by disease characteristics: subgroup analysis of PROMISE-1 and PROMISE-2
    Chakhava, George
    Cady, Roger
    Kassel, Eric
    Hirman, Joe
    Snapinn, Steve
    JOURNAL OF HEADACHE AND PAIN, 2019, 20
  • [8] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, Vincent
    Nagy, A. Jim
    Janelidze, Marina
    Giorgadze, Gvantsa
    Hirman, Joe
    Cady, Roger
    Mehta, Lahar
    Buse, Dawn C.
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 389 - 402
  • [9] Impact of baseline characteristics on the efficacy and safety of eptinezumab in patients with migraine: Subgroup analyses of PROMISE-1 and PROMISE-2
    Martin, V. T.
    Nagy, A. J.
    Janelidize, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    HEADACHE, 2021, 61 : 129 - 130
  • [10] Patients With Migraine Who Achieved a ≥75% Reduction in Monthly Migraine Days With Eptinezumab Treatment: Subgroup Analysis of PROMISE-1 and PROMISE-2
    Lipton, R. B.
    Charleston, L.
    Tassorelli, C.
    Brevig, T.
    Hirman, J.
    Cady, R.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 168 - 168
12345